Gena Wang
Stock Analyst at Barclays
(3.23)
# 1,054
Out of 4,412 analysts
132
Total ratings
42.06%
Success rate
2.33%
Average return
Main Sectors:
Top Industries:
29 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FDMT 4D Molecular Therapeutics | Initiates: Overweight | $45 | $23.25 | +93.55% | 1 | Apr 15, 2024 | |
| KOD Kodiak Sciences | Maintains: Underweight | $2 → $3 | $3.28 | -8.54% | 7 | Apr 1, 2024 | |
| SLDB Solid Biosciences | Maintains: Overweight | $8 → $21 | $8.98 | +133.85% | 4 | Mar 18, 2024 | |
| RGNX REGENXBIO | Maintains: Overweight | $45 → $55 | $16.19 | +239.72% | 5 | Mar 7, 2024 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $10 → $11 | $5.32 | +106.77% | 5 | Feb 29, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $141 → $185 | $128.77 | +43.67% | 5 | Feb 29, 2024 | |
| BEAM Beam Therapeutics | Maintains: Equal-Weight | $26 → $42 | $21.38 | +96.45% | 6 | Feb 28, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $61 → $80 | $53.91 | +48.40% | 10 | Feb 22, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $446 → $472 | $397.48 | +18.75% | 13 | Feb 6, 2024 | |
| LEGN Legend Biotech | Maintains: Overweight | $93 → $94 | $45.30 | +107.51% | 6 | Jan 24, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $125 → $111 | $80.91 | +37.19% | 3 | Nov 2, 2023 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $26 → $25 | $28.57 | -12.50% | 10 | Oct 27, 2023 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $11 → $9 | $0.52 | +1,638.12% | 2 | Aug 9, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $86 → $90 | $20.76 | +333.53% | 5 | Aug 7, 2023 | |
| VIR Vir Biotechnology | Maintains: Overweight | $59 → $41 | $8.23 | +398.18% | 2 | Jul 21, 2023 | |
| BLUE bluebird bio | Upgrades: Overweight | $7 → $8 | $0.92 | +766.93% | 7 | Jun 1, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Equal-Weight | $40 → $37 | $41.59 | -11.04% | 5 | May 4, 2023 | |
| ZYME Zymeworks | Maintains: Equal-Weight | $7 → $9 | $8.26 | +8.96% | 1 | Dec 22, 2022 | |
| ARCT Arcturus Therapeutics Holdings | Upgrades: Equal-Weight | $16 → $25 | $26.55 | -5.84% | 5 | Nov 2, 2022 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $240 → $236 | $143.31 | +64.68% | 3 | Oct 28, 2022 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Equal-Weight | $12 → $14 | $4.16 | +236.54% | 7 | Aug 5, 2022 | |
| CLLS Cellectis | Maintains: Overweight | $9 → $7 | $2.51 | +179.37% | 1 | May 13, 2022 | |
| MGTX MeiraGTx Holdings | Maintains: Overweight | $32 → $18 | $4.80 | +275.00% | 1 | May 13, 2022 | |
| AVRO AVROBIO | Maintains: Overweight | $6 → $4 | $1.21 | +230.58% | 3 | May 11, 2022 | |
| MRNA Moderna | Maintains: Overweight | n/a | $107.97 | - | 3 | Nov 5, 2021 | |
| AXNX Axonics | Maintains: Overweight | n/a | $66.69 | - | 1 | Aug 6, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | n/a | $44.24 | - | 5 | Aug 3, 2021 | |
| PBYI Puma Biotechnology | Downgrades: Underweight | n/a | $5.02 | - | 5 | Nov 2, 2018 | |
| ABEO Abeona Therapeutics | Initiates: Buy | n/a | $3.26 | - | 1 | Jan 6, 2017 |
4D Molecular Therapeutics
Apr 15, 2024
Initiates: Overweight
Price Target: $45
Current: $23.25
Upside: +93.55%
Kodiak Sciences
Apr 1, 2024
Maintains: Underweight
Price Target: $2 → $3
Current: $3.28
Upside: -8.54%
Solid Biosciences
Mar 18, 2024
Maintains: Overweight
Price Target: $8 → $21
Current: $8.98
Upside: +133.85%
REGENXBIO
Mar 7, 2024
Maintains: Overweight
Price Target: $45 → $55
Current: $16.19
Upside: +239.72%
Editas Medicine
Feb 29, 2024
Maintains: Equal-Weight
Price Target: $10 → $11
Current: $5.32
Upside: +106.77%
Sarepta Therapeutics
Feb 29, 2024
Maintains: Overweight
Price Target: $141 → $185
Current: $128.77
Upside: +43.67%
Beam Therapeutics
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $26 → $42
Current: $21.38
Upside: +96.45%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $61 → $80
Current: $53.91
Upside: +48.40%
Vertex Pharmaceuticals
Feb 6, 2024
Maintains: Overweight
Price Target: $446 → $472
Current: $397.48
Upside: +18.75%
Legend Biotech
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $45.30
Upside: +107.51%
BioMarin Pharmaceutical
Nov 2, 2023
Maintains: Overweight
Price Target: $125 → $111
Current: $80.91
Upside: +37.19%
PTC Therapeutics
Oct 27, 2023
Maintains: Equal-Weight
Price Target: $26 → $25
Current: $28.57
Upside: -12.50%
Sangamo Therapeutics
Aug 9, 2023
Maintains: Overweight
Price Target: $11 → $9
Current: $0.52
Upside: +1,638.12%
Intellia Therapeutics
Aug 7, 2023
Maintains: Overweight
Price Target: $86 → $90
Current: $20.76
Upside: +333.53%
Vir Biotechnology
Jul 21, 2023
Maintains: Overweight
Price Target: $59 → $41
Current: $8.23
Upside: +398.18%
bluebird bio
Jun 1, 2023
Upgrades: Overweight
Price Target: $7 → $8
Current: $0.92
Upside: +766.93%
Ionis Pharmaceuticals
May 4, 2023
Maintains: Equal-Weight
Price Target: $40 → $37
Current: $41.59
Upside: -11.04%
Zymeworks
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $8.26
Upside: +8.96%
Arcturus Therapeutics Holdings
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $26.55
Upside: -5.84%
Alnylam Pharmaceuticals
Oct 28, 2022
Maintains: Overweight
Price Target: $240 → $236
Current: $143.31
Upside: +64.68%
BioCryst Pharmaceuticals
Aug 5, 2022
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $4.16
Upside: +236.54%
Cellectis
May 13, 2022
Maintains: Overweight
Price Target: $9 → $7
Current: $2.51
Upside: +179.37%
MeiraGTx Holdings
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $4.80
Upside: +275.00%
AVROBIO
May 11, 2022
Maintains: Overweight
Price Target: $6 → $4
Current: $1.21
Upside: +230.58%
Moderna
Nov 5, 2021
Maintains: Overweight
Price Target: n/a
Current: $107.97
Upside: -
Axonics
Aug 6, 2021
Maintains: Overweight
Price Target: n/a
Current: $66.69
Upside: -
Ultragenyx Pharmaceutical
Aug 3, 2021
Maintains: Overweight
Price Target: n/a
Current: $44.24
Upside: -
Puma Biotechnology
Nov 2, 2018
Downgrades: Underweight
Price Target: n/a
Current: $5.02
Upside: -
Abeona Therapeutics
Jan 6, 2017
Initiates: Buy
Price Target: n/a
Current: $3.26
Upside: -